Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 4,248 GBp
Change Today +79.50 / 1.91%
Volume 2.2M
As of 11:35 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

4,228 GBp
Previous Close
4,168 GBp
Day High
4,263 GBp
Day Low
4,194 GBp
52 Week High
04/23/15 - 4,906 GBp
52 Week Low
08/24/15 - 3,746 GBp
Market Cap
Average Volume 10 Days
0.94 GBp
Shares Outstanding
3.04 GBp
Dividend Yield
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products include Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. It also engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., Pharmacyclics Inc., The University of Manchester, and Janssen Research & Development, LLC., as well as a strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. It also has a license from Heptares Therapeutics Ltd. to develop, manufacture, and commercialize the adenosine A2A receptor antagonist, HTL-1071. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

AstraZeneca Announces Availability of New Dose of Brilinta in US Pharmacies

AstraZeneca announced that BRILINTA® (ticagrelor) 60-mg tablets are now available in US pharmacies. On September 3, 2015, the US Food and Drug Administration (FDA) approved a new 60-mg dosage strength for BRILINTA to be used in patients with a history of heart attack beyond the first year. BRILINTA is approved to reduce the rate of cardiovascular (CV) death, myocardial infarction ([MI], also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, BRILINTA is superior to clopidogrel. BRILINTA is the first and only FDA approved oral antiplatelet to demonstrate superior reductions in CV death versus clopidogrel at 12 months. The dosing of BRILINTA in the management of ACS is 90 mg twice daily during the first year after an ACS event. After one year, patients with a history of heart attack can now be treated with 60 mg twice daily. BRILINTA must be used with a daily maintenance dose of aspirin of 75-100mg. AstraZeneca is committed to supporting patient access to BRILINTA and connecting patients with the information and support they need. For patients who have been prescribed BRILINTA, AstraZeneca offers the BRILINTA Patient Support Service (BPSS) tool that provides resources and support to help patients and caregivers from hospital discharge throughout the ACS treatment journey. To help loved ones, the program offers important patient education and coaching in addition to savings offers, refill reminders, personal pharmacy locator, co-pay calculator, and coverage verification and information.

AstraZeneca PLC Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:40 PM

AstraZeneca PLC Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:40 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Robert Iannone, SVP, Head of Immuno-oncology, Global Medicines Development.

HHS to Collaborate with Astrazeneca for Biodefense Preparedness Plan

HHS will collaborate with AstraZeneca on an antibiotic initiative as part of a biodefense preparedness plan for dealing with public health threats. The public-private partnership will bring together for the second time the Biomedical Advanced Research and Development Authority wing of the HHS with a drug company to develop investigational medications that could potentially be used to ward off bioterrorism and deadly bacterial infections or pandemics. With $50 million in up-front BARDA funding and up to $170 million down the road, depending on the products, the agreement is a turn toward investing in a roster of drugs, rather than single products to speed up the process and create more options. HHS and AZ have eyed ATM-AVI (Aztreonam and Avibactam) to study its use against meliodosis, glanders and the plague.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,247.50 GBp +79.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $146.32 USD +3.12
AbbVie Inc $56.68 USD +0.86
Biogen Inc $286.55 USD -3.80
Celgene Corp $116.62 USD +0.18
Eli Lilly & Co $86.57 USD -0.95
View Industry Companies

Industry Analysis


Industry Average

Valuation AZN Industry Range
Price/Earnings 67.8x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 67.8x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at